All In Biotech

Free tool

FAERS Monitor: Journavx

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219209 or its brand name (Journavx, Suzetrigine). Reports on generic versions are filed under their own applications.

Reports

1,649

Serious

222

13% of reports

Hospitalization

88

Death reported

11

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use249
  • pruritus190
  • rash147
  • paraesthesia111
  • nausea104
  • dizziness93
  • drug ineffective82
  • muscle spasms78
  • fatigue62
  • headache57
  • somnolence53
  • diarrhoea48
  • insomnia48
  • hypoaesthesia47
  • pain47

Reports by year received

View as table
YearReports
20203
20221
20242
2025670
2026973

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,510 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
paraesthesiaSignal1119.07.5787
pruritusSignal1906.35.5859
muscle spasmsSignal785.44.4279
rashSignal1474.33.7377
hypoaesthesiaSignal474.03.0104
off label useSignal2493.63.2492
somnolenceSignal533.42.686
dizzinessSignal932.42.075
insomniaSignal482.31.734
nausea1041.71.429
headache571.20.91
fatigue621.00.80
pain471.00.70
diarrhoea480.90.70
drug ineffective820.80.64

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.